Suven Pharma, Cohance Lifesciences announce merger
The overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.
Read MoreThe overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.
Read MoreThe overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.
Read MoreThe overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.
Read MoreThe overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.
Read MoreThe overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.
Read MoreThe overall transaction is expected to conclude over the next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals.
Read More